Sagimet Biosciences (SGMT) Liabilities and Shareholders Equity (2023 - 2024)
Sagimet Biosciences (SGMT) has 2 years of Liabilities and Shareholders Equity data on record, last reported at $174.8 million in Q3 2024.
- For Q3 2024, Liabilities and Shareholders Equity rose 69.81% year-over-year to $174.8 million; the TTM value through Dec 2024 reached $558.3 million, up 152.47%, while the annual FY2023 figure was $96.7 million, N/A changed from the prior year.
- Liabilities and Shareholders Equity reached $174.8 million in Q3 2024 per SGMT's latest filing, down from $189.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $194.5 million in Q1 2024 and bottomed at $21.5 million in Q2 2023.